IL-33 and IL-33 receptors in host defense and diseases

Allergology International

Volumn 59, Issue 2, 2010, Pages 143-160

  Oboki, Keisuke ^a   Ohno, Tatsukuni ^a   Kajiwara, Naoki ^a,b   Saito, Hirohisa ^a,b   Nakae, Susumu ^a,b,c  

^a NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Allergy; Autoimmunity; Basophil; Chronic disease; Eosinophil; Host defense; IL 33; Mast cell; ST2

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 33; INTERLEUKIN 33 RECEPTOR; INTERLEUKIN 5; INTERLEUKIN RECEPTOR; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; IL1RL1 PROTEIN, MOUSE; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; TOLL LIKE RECEPTOR;

ALLERGY; BASOPHIL; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; EOSINOPHIL; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MAST CELL; NEMATODE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TH2 CELL; ANIMAL; AUTOIMMUNE DISEASE; GENETIC POLYMORPHISM; GENETICS; HOST PATHOGEN INTERACTION; HYPERSENSITIVITY; IMMUNITY; IMMUNOLOGY; INFECTION; MOUSE;

ANIMALS; AUTOIMMUNE DISEASES; HOST-PATHOGEN INTERACTIONS; HUMANS; HYPERSENSITIVITY; IMMUNITY; INFECTION; INFLAMMATION; INTERLEUKINS; MICE; POLYMORPHISM, GENETIC; RECEPTORS, CELL SURFACE; RECEPTORS, INTERLEUKIN; TH2 CELLS; TOLL-LIKE RECEPTORS;

EID: 77954555721     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.10-RAI-0186     Document Type: Review

References (154)

1. Onda H, Kasuya H, Takakura K et al. Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. J Cereb Blood Flow Metab 1999;19:1279-88.
2. Baekkevold ES, Roussigne M, Yamanaka T et al. Molecu-lar characterization of NF-HEV, a nuclear factor preferentially expressedinhuman high endothelial venules. Am J Pathol 2003;163:69-79.
3. Schmitz J, Owyang A, Oldham E et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23:479-90.
4. Ohno T, Oboki K, Kajiwara N et al. Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J Immunol 2009;183:7890-7.
5. Carriere V, Roussel L, Ortega N et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A 2007;104:282-7.
6. Roussel L, Erard M, Cayrol C, Girard JP. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep 2008; 9:1006-12.
7. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007;179:2551-5.
8. Ali S, Huber M, Kollewe C, Bischoff SC, Falk W, Martin MU. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci USA 2007;104:18660-5.
9. O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008; 226:10-8.
10. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008;223:20-38.
11. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009;27: 519-50.
12. Iwahana H, Yanagisawa K, Ito-Kosaka A et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem 1999;264:397-406.
13. Tago K, Noda T, Hayakawa M et al. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem Biophys Res Commun 2001;285:1377-83.
14. Iwahana H, Hayakawa M, Kuroiwa K et al. Molecular cloning of the chicken ST2 gene and a novel variant form of the ST2 gene product, ST2LV. Biochim Biophys Acta 2004;1681:1-14.
15. Bulek K, Swaidani S, Qin J et al. The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response. J Immunol 2009;182: 2601-9.
16. Garlanda C, Anders HJ, Mantovani A. TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol 2009; 30:439-46.
17. Garlanda C, Riva F, Polentarutti N et al. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of theIL-1receptorfamily. Proc Natl Acad Sci U S A 2004; 101:3522-6.
18. Lecart S, Lecointe N, Subramaniam A et al. Activated, but not resting human Th2 cells, in contrast to Th1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface. Eur J Immunol 2002;32: 2979-87.
19. Lohning M, Stroehmann A, Coyle AJ et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A 1998;95:6930-5.
20. Nakae S, Iwakura Y, Suto H, Galli SJ. Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol 2007;81:1258-68.
21. Hoshino K, Kashiwamura S, Kuribayashi K et al. Theab-sence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J Exp Med 1999;190:1541-8.
22. Townsend MJ, Fallon PG, Matthews DJ, Jolin HE, McKenzie AN. T1/ST2-deficient mice demonstrate the importance ofT1/ST2 in developing primary T helper cell type 2 responses. J Exp Med 2000;191:1069-76.
23. Kondo Y, Yoshimoto T, Yasuda K et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol 2008;20:791-800.
24. Kurowska-Stolarska M, Kewin P, Murphy G et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008;181:4780-90.
25. Guo L, Wei G, Zhu J et al. IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proc Natl Acad Sci USA 2009;106:13463-8.
26. Pecaric-Petkovic T, Didichenko SA, Kaempfer S, Spiegl N, Dahinden CA. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 2009;113:1526-34.
27. Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 2008;20:1019-30.
28. Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 2007;37:2779-86.
29. Kropf P, Schopf LR, Chung CL et al. Expression of Th2 cytokines and the stable Th2 marker ST2L in the absence of IL-4 during Leishmania major infection. Eur J Immunol 1999;29:3621-8.
30. Kropf P, Herath S, Klemenz R, Muller I. Signaling through the T1/ST2 molecule is not necessary for Th2 differentiation but is important for the regulation of type 1 responses in nonhealing Leishmania major infection. Infect Immun 2003;71:1961-71.
31. Chan WL, Pejnovic N, Lee CA, Al-Ali NA. Human IL-18 receptor and ST2L are stable and selective markers for the respective type 1 and type 2 circulating lymphocytes. J Immunol 2001;167:1238-44.
32. McGuirk P, McCann C, Mills KH. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med 2002;195:221-31.
33. Moritz DR, Rodewald HR, Gheyselinck J, Klemenz R. The IL-1 receptor-related T1 antigenisexpressedonimma-ture and mature mast cells and on fetal blood mast cell progenitors. J Immunol 1998; 161:4866-74.
34. Chen CC, Grimbaldeston MA, Tsai M, Weissman IL, Galli SJ. Identification of mast cell progenitors in adult mice. Proc Natl Acad Sci USA 2005;102:11408-13.
35. Iikura M, Suto H, Kajiwara N et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest 2007;87:971-8.
36. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007; 179:2051-4.
37. Ho LH, Ohno T, Oboki K et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol 2007;82:1481-90.
38. Moulin D, Donze O, Talabot-Ayer D, Mezin F, Palmer G, Gabay C. Interleukin (IL)-33 induces the release of proinflammatory mediators by mast cells. Cytokine 2007;40: 216-25.
39. Pushparaj PN, Tay HK, H'Ng SC et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA 2009;106:9773-8.
40. Min B, Le Gros G, Paul WE. Basophils: a potential liaison between innate and adaptive immunity. Allergol Int 2006; 55:99-104.
41. Sullivan BM, Locksley RM. Basophils: a nonredundant contributor to host immunity. Immunity 2009;30:12-20.
42. Perrigoue JG, Saenz SA, Siracusa MC et al. MHC class II-dependent basophil-CD4+ T cell interactions promote T (H)2 cytokine-dependent immunity. Nat Immunol 2009; 10:697-705.
43. Sokol CL, Chu NQ, Yu S, Nish SA, Laufer TM, Medzhitov R. Basophils function as antigen-presenting cells for an allergen-induced T helper type 2 response. Nat Immunol 2009;10:713-20.
44. Yoshimoto T, Yasuda K, Tanaka H et al. Basophils contribute to T(H)2-IgE responses in vivo via IL-4 production and presentation of peptide-MHC class II complexes to CD4+ T cells. Nat Immunol 2009;10:706-12.
45. Suzukawa M, Iikura M, Koketsu R et al. AnIL-1cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol 2008;181:5981-9.
46. Schneider E, Petit-Bertron AF, Bricard R et al. IL-33Activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting he-matopoietic growth factor production. J Immunol 2009; 183:3591-7.
47. Kroeger KM, Sullivan BM, Locksley RM. IL-18 and IL-33 elicit Th2 cytokines from basophils via a MyD88- and p38 alpha-dependent pathway. JLeukocBiol 2009;86:769-78.
48. Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol 2008;121:1484-90.
49. Suzukawa M, Koketsu R, Iikura M et al. Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest 2008;88:1245-53.
50. Bourgeois E, Van LP, Samson M et al. The pro-Th2 cy-tokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol 2009;39:1046-55.
51. Mayuzumi N, Matsushima H, Takashima A. IL-33 promotes DC development in BM culture by triggering GM-CSF production. Eur J Immunol 2009;39:3331-42.
52. Rank MA, Kobayashi T, Kozaki H, Bartemes KR, Squillace DL, Kita H. IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol 2009; 123:1047-54.
53. Saenz SA, Taylor BC, Artis D. Welcome to the neighborhood: epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites. Immunol Rev 2008;226:172-90.
54. Soumelis V, Reche PA, Kanzler H et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002;3:673-80.
55. Ito T, Wang YH, Duramad O et al. TSLP-activated dendritic cells induce an inflammatory Thelper type 2 cell response through OX40 ligand. J Exp Med 2005;202:1213-23.
56. Wang YH, Angkasekwinai P, Lu N et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J Exp Med 2007;204:1837-47.
57. Omori M, Ziegler S. Induction of IL-4 expression in CD4 (+) T cells by thymic stromal lymphopoietin. J Immunol 2007;178:1396-404.
58. Angkasekwinai P, Park H, Wang YH et al. Interleukin 25 promotes the initiation of proallergic type 2 responses. J Exp Med 2007;204:1509-17.
59. Sweet MJ, Leung BP, Kang D et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol 2001;166:6633-9.
60. Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y. ST 2 protein induced by inflammatory stimuli can modulate acute lung inflammation. Biochem Biophys Res Commun 2002;299:18-24.
61. Kumar S, Tzimas MN, Griswold DE, Young PR. Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli. Biochem Biophys Res Commun 1997;235:474-8.
62. Saccani S, Polentarutti N, Penton-Rol G, Sims JE, Man-tovani A. Divergent effects of LPS on expression of IL-1 receptor family members in mononuclear phagocytes in vitro and in vivo. Cytokine 1998;10:773-80.
63. Espinassous Q, Garcia-de-Paco E, Garcia-Verdugo I et al. IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J Immunol 2009;183:1446-55.
64. Xu D, Chan WL, Leung BP et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 1998;187:787-94.
65. Brint EK, Xu D, Liu H et al. ST2 is an inhibitor of inter-leukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 2004;5:373-9.
66. Glaccum MB, Stocking KL, Charrier K et al. Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. J Immunol 1997;159:3364-71.
67. Hirsch E, Irikura VM, Paul SM, Hirsh D. Functions of in-terleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci U S A 1996;93: 11008-13.
68. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23-35.
69. Ma J, Chen T, Mandelin J et al. Regulation of macrophage activation. Cell Mol Life Sci 2003;60:2334-46.
70. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Lo-cati M. The chemokine system in diverse forms of macro-phage activation and polarization. Trends Immunol 2004; 25:677-86.
71. Sica A, Larghi P, Mancino A et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008;18: 349-55.
72. Kurowska-Stolarska M, Stolarski B, Kewin P et al. IL-33 amplifies the polarization of alternatively activated macro-phages that contribute to airway inflammation. J Immunol 2009;183:6469-77.
73. Allakhverdi Z, Comeau MR, Smith DE et al. CD34+ he-mopoietic progenitor cells are potent effectors of allergic inflammation. J Allergy Clin Immunol 2009;123:472-8.
74. Moro K, Yamada T, Tanabe M et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Scalymphoid cells. Nature 2010;463:540-4.
75. Bianchi ME. DAMPs, PAMPs alarmins: all we need to know about danger. J Leukoc Biol 2007;81:1-5.
76. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5:331-42.
77. Luthi AU, Cullen SP, McNeela EA et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009;31:84-98.
78. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U SA 2009;106:9021-6.
79. Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem 2009;284:19420-6.
80. Sacks D, Anderson C. Re-examination of the immunosup-pressive mechanisms mediating non-cure of Leishmania infection in mice. Immunol Rev 2004;201:225-38.
81. Kropf P, Bickle Q, Herath S, Klemenz R, Muller I. Organ-specific distribution of CD4+ T1/ST2+ Th2 cells in Leishmania major infection. Eur J Immunol 2002;32:2450-9.
82. Aliberti J, Jankovic D, Sher A. Turning it on and off: regulation of dendritic cell function in Toxoplasma gondii infection. Immunol Rev 2004;201:26-34.
83. Jones LA, Roberts F, Nickdel MB et al. IL-33 receptor (T1 /ST2) signalling is necessary to prevent the development of encephalitis in mice infected with Toxoplasma gondii. Eur J Immunol 2010;40:426-36.
84. Finkelman FD, Shea-Donohue T, Morris SC et al. Interleukin-4- and interleukin-13-mediated host protection against intestinal nematode parasites. Immunol Rev 2004; 201:139-55.
85. Senn KA, McCoy KD, Maloy KJ et al. T1-deficient and T1-Fc-transgenic mice develop a normal protective Th2-type immune response following infection with Nippostrongy-lus brasiliensis. Eur J Immunol 2000;30:1929-38.
86. Pearce EJ, M Kane C, Sun J, J Taylor J, McKee AS, Cervi L. Th2 response polarization during infection with the helminth parasite Schistosoma mansoni. Immunol Rev 2004;201:117-26.
87. Wynn TA, Thompson RW, Cheever AW, Mentink-Kane MM. Immunopathogenesis of schistosomiasis. Immunol Rev 2004;201:156-67.
88. Cliffe LJ, Grencis RK. The Trichuris muris system: a paradigm of resistance and susceptibility to intestinal nema-tode infection. Adv Parasitol 2004;57:255-307.
89. Humphreys NE, Xu D, Hepworth MR, Liew FY, Grencis RK. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol 2008;180:2443-9.
90. Huang X, Du W, Barrett RP, Hazlett LD. ST2 is essential for Th2 responsiveness and resistance to pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 2007;48: 4626-33.
91. Hazlett LD, McClellan SA, Barrett RP et al. IL-33shifts macrophage polarization, promoting resistance against Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 2010;51:1524-32.
92. Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009;27:393-422.
93. Wieland CW, van der Windt GJ, Florquin S, McKenzie AN, van der Poll T. ST2 deficient mice display a normal host defense against pulmonary infection with Mycobac-terium tuberculosis. Microbes Infect 2009;11:524-30.
94. Garlanda C, Di Liberto D, Vecchi A et al. Damping excessive inflammation and tissue damage in Mycobacterium tuberculosis infection by Toll IL-1 receptor 8/single Ig IL-1-related receptor, a negative regulator of IL-1/TLR signaling. J Immunol 2007;179:3119-25.
95. Wagenaar JF, Gasem MH, Goris MG et al. Soluble ST2 levels are associated with bleeding in patients with severe Leptospirosis. PLoS Negl Trop Dis 2009;3:e453.
96. Becerra A, Warke RV, de Bosch N, Rothman AL, Bosch I. Elevated levels of soluble ST2 protein in dengue virus infected patients. Cytokine 2008;41:114-20.
97. Hudson CA, Christophi GP, Gruber RC, Wilmore JR, Lawrence DA, Massa PT. Induction of IL-33 expression and activity in central nervous system glia. J Leukoc Biol 2008; 84:631-43.
98. Walzl G, Matthews S, Kendall S et al. Inhibition of T1/ST 2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopa-thology. J Exp Med 2001;193:785-92.
99. Kuchler AM, Pollheimer J, Balogh J et al. Nuclear interleukin-33 is generally expressed in resting endothe-lium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol 2008;173:1229-42.
100. Choi YS, Choi HJ, Min JK et al. IL-33 induces angiogene-sis and vascular permeability through ST2/TRAF6-mediated endothelial NO production. Blood 2009;114: 3117-26.
101. Kuroiwa K, Li H, Tago K et al. Construction of ELISA system to quantify human ST2 protein in sera of patients. Hy-bridoma 2000;19:151-9.
102. Oshikawa K, Kuroiwa K, Tago K et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001;164: 277-81.
103. Prefontaine D, Lajoie-Kadoch S, Foley S et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol 2009;183: 5094-103.
104. Gudbjartsson DF, Bjornsdottir US, Halapi E et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet 2009; 41:342-7.
105. Reijmerink NE, Postma DS, Bruinenberg M et al. Association of IL1RL1, IL18R1, and IL18RAP gene cluster polymorphisms with asthma and atopy. J Allergy Clin Immunol 2008;122:651-4. e8.
106. Ali M, Zhang G, Thomas WR et al. Investigations into the role of ST2 in acute asthma in children. Tissue Antigens 2009;73:206-12.
107. Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y. Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin Exp Allergy 2002;32: 1520-6.
108. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007;282:26369-80.
109. Mangan NE, Dasvarma A, McKenzie AN, Fallon PG. T1/ ST2 expression on Th2 cells negatively regulates allergic pulmonary inflammation. Eur J Immunol 2007;37:1302-12.
110. Meisel C, Bonhagen K, Lohning M et al. Regulation and function ofT1/ST2 expression on CD4+T cells: induction of type 2 cytokine production by T1/ST2 cross-linking. J Immunol 2001;166:3143-50.
111. Coyle AJ, Lloyd C, Tian J et al. Crucial role of the inter-leukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med 1999;190:895-902.
112. Kearley J, Buckland KF, Mathie SA, Lloyd CM. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med 2009;179:772-81.
113. Liu X, Li M, Wu Y, Zhou Y, Zeng L, Huang T. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun 2009;386:181-5.
114. Cohn L, Homer RJ, Marinov A, Rankin J, Bottomly K. Induction of airway mucus production By T helper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production. J Exp Med 1997;186:1737-47.
115. Shimizu M, Matsuda A, Yanagisawa K et al. Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum Mol Genet 2005;14:2919-27.
116. Sakashita M, Yoshimoto T, Hirota T et al. Association of serum interleukin-33 level and the interleukin-33 genetic variant with Japanese cedar pollinosis. Clin Exp Allergy 2008;38:1875-81.
117. Castano R, Bosse Y, Endam LM, Desrosiers M. Evidence of association of interleukin-1 receptor-like 1 gene polymorphisms with chronic rhinosinusitis. Am J Rhinol Allergy 2009;23:377-84.
118. Hartmann B, Staedtler F, Hartmann N, Meingassner J, Fi-rat H. Gene expression profiling of skin and draining lymph nodes of rats affected with cutaneous contact hy-persensitivity. Inflamm Res 2006;55:322-34.
119. Matsuda A, Okayama Y, Terai N et al. TheRoleof interleukin-33 in chronic allergic conjunctivitis. Invest Ophthalmol Vis Sci 2009;50:4646-52.
120. Fraser A, Moore M, Jongbloed S, Gracie A, McInnes IB. Elevated soluble ST2 and cytokine levels in synovial fluids of patients with inflammatory synovitis. Ann Rheum Dis 2006;65(Suppl 1):A10.
121. Xu D, Jiang HR, Kewin P et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A 2008;105:10913-8.
122. Palmer G, Talabot-Ayer D, Lamacchia C et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum 2009;60:738-49.
123. Matsuyama Y, Okazaki H, Tamemoto H et al. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol 2010;37:18-25.
124. Leung BP, Xu D, Culshaw S, McInnes IB, Liew FY. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 2004;173:145-50.
125. Tesch GH, Allen TJ. Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology (Carlton) 2007; 12:261-6.
126. Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 2008;51:216-26.
127. Lamhamedi-Cherradi SE, Zheng SJ, Maguschak KA, Pe-schon J, Chen YH. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/-mice. Nat Immunol 2003;4:255-60.
128. Pakala SV, Chivetta M, Kelly CB, Katz JD. In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha. J Exp Med 1999;189:1053-62.
129. Zdravkovic N, Shahin A, Arsenijevic N, Lukic ML, Mensah-Brown EP. Regulatory T cells and ST2 signaling control diabetes induction with multiple low doses of streptozotocin. Mol Immunol 2009;47:28-36.
130. Miller AM, Xu D, Asquith DL et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008;205:339-46.
131. Farrer LA, Cupples LA, Haines JL et al. Effects of age, sex, and ethnicity on the association between apolipopro-tein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-56.
132. Chapuis J, Hot D, Hansmannel F et al. Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Mol Psychiatry 2009;14:1004-16.
133. Seidelin JB, Bjerrum JT, Coskun M, Widjaya B, Vainer B, Nielsen OH. IL-33 is upregulated in colonocytes of ulcera-tive colitis. Immunol Lett 2010;128:80-5.
134. Beltran CJ, Nunez LE, Diaz-Jimenez D et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis 2010. In press.
135. Axelsson LG, Landstrom E, Goldschmidt TJ, Gronberg A, Bylund-Fellenius AC. Dextran sulfate sodium (DSS) induced experimental colitis in immunodeficient mice: effects in CD4(+)-cell depleted, athymic and NK-cell depleted SCID mice. Inflamm Res 1996;45:181-91.
136. Ueno Y, Tanaka S, Sumii M et al. SingledoseofOCHim-proves mucosal T helper type 1/T helper type 2 cytokine balance and prevents experimental colitis in the presence of valpha14 natural killer T cells in mice. Inflamm Bowel Dis 2005;11:35-41.
137. Minocha A, Thomas C, Omar R. Lack of crucial role of mast cells in pathogenesis of experimental colitis in mice. Dig Dis Sci 1995;40:1757-62.
138. Heimesaat MM, Fischer A, Siegmund B et al. Shiftto-wards pro-inflammatory intestinal bacteria aggravates acute murine colitis via Toll-like receptors 2 and 4. PLoS One 2007;2:e662.
139. Xiao H, Gulen MF, Qin J et al. The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial ho-meostasis, inflammation, and tumorigenesis. Immunity 2007;26:461-75.
140. Manetti M, Ibba-Manneschi L, Liakouli V et al. TheIL-1-like cytokine IL-33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann Rheum Dis 2010;69: 598-605.
141. Rankin AL, Mumm JB, Murphy E et al. IL-33 Induces IL-13-Dependent Cutaneous Fibrosis. J Immunol 2010;184: 1526-35.
142. Kuroiwa K, Arai T, Okazaki H, Minota S, Tominaga S. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun 2001;284:1104-8.
143. Mok MY, Huang FP, Ip WK et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology(Oxford) 2010;49:520-7.
144. Lech M, Kulkarni OP, Pfeiffer S et al. Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens. J Exp Med 2008;205:1879-88.
145. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003;107:721-6.
146. Shimpo M, Morrow DA, Weinberg EO et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004;109:2186-90.
147. Bartunek J, Delrue L, Van Durme F et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 2008;52: 2166-74.
148. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biome-chanically induced and cardioprotective signaling system. J Clin Invest 2007; 117:1538-49.
149. Seki K, Sanada S, Kudinova AY et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009;2:684-91.
150. Marvie P, Lisbonne M, L'Helgoualc'h A et al. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med. Epub 2009 Jun 5.
151. Amatucci A, Novobrantseva T, Gilbride K, Brickelmaier M, Hochman P, Ibraghimov A. Recombinant ST2 boosts hepatic Th2 response in vivo. J Leukoc Biol 2007;82:124-32.
152. Verri WA Jr, Schivo IR, Cunha TM, Liew FY, Ferreira SH, Cunha FQ. Interleukin-18 induces mechanical hyperno-ciception in rats via endothelin acting on ETB receptors in a morphine-sensitive manner. J Pharmacol Exp Ther 2004;310:710-7.
153. White FA, Jones KJ. IL-1beta signaling initiates inflammatory hypernociception. Brain Behav Immun 2008;22: 1014-5.
154. Verri WA Jr, Guerrero AT, Fukada SY et al. IL-33mediates antigen-induced cutaneous and articular hyperno-ciception in mice. Proc Natl Acad Sci U S A 2008;105: 2723-8.